Lv72
4600 积分 2023-01-28 加入
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
14天前
已完结
Recovery Animals in Toxicology Studies: An Innovation and Quality Consortium Perspective on Best Practices With Case Study Examples
1个月前
已完结
Human Dose and Pharmacokinetic Predictions for Biologics at Boehringer Ingelheim: A Retrospective Analysis
3个月前
已完结
Dermatologic Toxicities of Antibody-Drug Conjugates
3个月前
已完结
Toxicologic Pathology Forum*: Opinion on the Interpretation of Statistical Significance Testing Results From Anatomic and Clinical Pathology Data in Nonclinical Safety Studies
3个月前
已完结
Molecular glue meets antibody: next-generation antibody–drug conjugates
3个月前
已完结
Rethinking the Necessity of Long-term Toxicity Studies for Biotherapeutics Using Weight of Evidence Assessment
3个月前
已完结
Dual-payload Antibody–drug Conjugates: Taking a Dual Shot
4个月前
已完结
Drug-Linkers in Antibody–Drug Conjugates: Perspective on Current Industry Practices
5个月前
已完结
Comparisons of PK-Sim® and R Program for Physiologically Based Pharmacokinetic Model Development for Broiler Chickens and Laying Hens: Meloxicam as a Case Study
6个月前
已关闭
皖公网安备34019202002308
